John P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine

home / authors / john-p-leonard-md-new-york-presbyterian-weill-cornell-medical-center

Articles

Next Steps in Mantle Cell Lymphoma

Next Steps in Mantle Cell Lymphoma

John P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine;Krish Patel, MD, Swedish Medical Center;Tycel Jovelle Phillips, MD, University of Michigan;Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center
March 2nd 2021

Read More

MRD Assessment in Mantle Cell Lymphoma

MRD Assessment in Mantle Cell Lymphoma

John P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine;Krish Patel, MD, Swedish Medical Center;Tycel Jovelle Phillips, MD, University of Michigan;Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center
March 2nd 2021

Read More

Novel Therapies in the Pipeline in Mantle Cell Lymphoma

Novel Therapies in the Pipeline in Mantle Cell Lymphoma

John P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine;Krish Patel, MD, Swedish Medical Center;Tycel Jovelle Phillips, MD, University of Michigan;Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center
March 2nd 2021

Read More

MCL: Emerging BTKi-Combination Approaches

MCL: Emerging BTKi-Combination Approaches

John P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine;Krish Patel, MD, Swedish Medical Center;Tycel Jovelle Phillips, MD, University of Michigan;Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center
February 23rd 2021

Read More

Emerging BTK Inhibitors in Mantle Cell Lymphoma

Emerging BTK Inhibitors in Mantle Cell Lymphoma

John P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine;Krish Patel, MD, Swedish Medical Center;Tycel Jovelle Phillips, MD, University of Michigan;Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center
February 23rd 2021

Read More

CAR T-Cell Therapy for R/R Mantle Cell Lymphoma

CAR T-Cell Therapy for R/R Mantle Cell Lymphoma

John P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine;Krish Patel, MD, Swedish Medical Center;Tycel Jovelle Phillips, MD, University of Michigan;Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center
February 16th 2021

Read More

Venetoclax in Mantle Cell Lymphoma

Venetoclax in Mantle Cell Lymphoma

John P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine;Krish Patel, MD, Swedish Medical Center;Tycel Jovelle Phillips, MD, University of Michigan;Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center
February 16th 2021

Read More

BTK Inhibitors for Relapsed MCL: Important Considerations

BTK Inhibitors for Relapsed MCL: Important Considerations

John P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine;Krish Patel, MD, Swedish Medical Center;Tycel Jovelle Phillips, MD, University of Michigan;Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center
February 9th 2021

Read More

Selecting a BTKi for Relapsed MCL Treatment

Selecting a BTKi for Relapsed MCL Treatment

John P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine;Krish Patel, MD, Swedish Medical Center;Tycel Jovelle Phillips, MD, University of Michigan;Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center
February 9th 2021

Read More

Acalabrutinib and Zanubrutinib for Relapsed MCL

Acalabrutinib and Zanubrutinib for Relapsed MCL

John P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine;Krish Patel, MD, Swedish Medical Center;Tycel Jovelle Phillips, MD, University of Michigan;Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center
February 2nd 2021

Read More

BTK Inhibitors for Relapsed Mantle Cell Lymphoma

BTK Inhibitors for Relapsed Mantle Cell Lymphoma

John P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine;Krish Patel, MD, Swedish Medical Center;Tycel Jovelle Phillips, MD, University of Michigan;Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center
February 2nd 2021

Read More

Lenalidomide and Bortezomib for Mantle Cell Lymphoma

Lenalidomide and Bortezomib for Mantle Cell Lymphoma

John P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine;Krish Patel, MD, Swedish Medical Center;Tycel Jovelle Phillips, MD, University of Michigan;Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center
January 26th 2021

Read More

Go-To Treatment Regimens in Mantle Cell Lymphoma

Go-To Treatment Regimens in Mantle Cell Lymphoma

John P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine;Krish Patel, MD, Swedish Medical Center;Tycel Jovelle Phillips, MD, University of Michigan;Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center
January 26th 2021

Read More

Treatment Approaches in Mantle Cell Lymphoma

Treatment Approaches in Mantle Cell Lymphoma

John P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine;Krish Patel, MD, Swedish Medical Center;Tycel Jovelle Phillips, MD, University of Michigan;Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center
January 19th 2021

Read More

Accurately Diagnosing Mantle Cell Lymphoma

Accurately Diagnosing Mantle Cell Lymphoma

John P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine;Krish Patel, MD, Swedish Medical Center;Tycel Jovelle Phillips, MD, University of Michigan;Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center
January 19th 2021

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need